Encouragingly, a phase I clinical trial evaluating sequential therapy with an anti-PD-L1 antibody, durvalumab, following MEK inhibitor treatment has reported evidence of activity in BRAF WT melanoma patients [36]. The gene discussed is MAP2K7; the disease is melanoma.